Introduction {#S0001}
============

Vascular endothelial growth factor (VEGF), isolated by Ferrara and Davis-Smyth \[[@CIT0001]\] in 1989, is a potent endothelial cell mitogen that promotes the proliferation of vascular endothelial cells. Vascular endothelial growth factor plays a pivotal role in the regulation of physiological and pathological angiogenesis. There have been lots of reports on the role of VEGF-mediated angiogenesis and vascular permeability changes in chronic microvascular complications of diabetes. The association of VEGF and diabetic neuropathy has attracted attention in recent years. For example, Deguchi *et al*. \[[@CIT0002]\] found that the serum VEGF level was significantly increased in diabetic neuropathy. Currently it is believed that VEGF affects nerve fibers by changing the structure and function of endothelial cells. Vascular endothelial growth factor can increase capillary permeability, promote the synthesis of extracellular matrix and promote the proliferation and hypertrophy of endothelial cells. Also VEGF can induce basement membrane thickening and aggravate capillary obstruction. In addition, VEGF can impair the barrier function of the basement membrane and increase the endoneurial vascular permeability, leading to nerve fiber ischemia and hypoxia, and thus contributing to the occurrence of neuropathy \[[@CIT0003]\]. On the other hand, Sondell *et al*. \[[@CIT0004]\] and Tremolada *et al*. \[[@CIT0005]\] reported that where there was ischemia and hypoxia, high expression of VEGF was protective for ischemic neuronal damage. This was because VEGF could not only promote angiogenesis of the nervous system but also have direct neurotrophic effects on the nervous system.

There are multiple polymorphism loci in the VEGF gene. The 936C/T gene polymorphism located in the 3'-untranslated region (3'-UTR) is associated with the expression level of VEGF \[[@CIT0006], [@CIT0007]\]. However, there have been no reports on the association of VEGF 936C/T polymorphism and type 2 diabetes with peripheral neuropathy so far. In this study we examined the relationship between VEGF 936C/T polymorphism and VEGF expression level in type 2 diabetic peripheral neuropathy.

Material and methods {#S0002}
====================

Subjects {#S20003}
--------

According to the diagnostic and exclusion criteria and typing standard for diabetes suggested by the WHO experts in 1999, unrelated patients with type 2 diabetes continuously attending the same hospital during 3 years were enrolled in this study. Diabetic peripheral neuropathy was diagnosed based on the diagnostic criteria suggested by Practical Endocrinology \[[@CIT0008]\]. The clinical symptoms (such as symptoms of motor and/or sensory neuropathy) were examined and an electromyography (EMG) examination (for conduction disorders of motor and/or sensory nerves) was performed. A total of 388 patients with type 2 diabetes were selected. The pure diabetes group (DM) was composed of 184 cases, of which 92 cases were male and 92 cases were female, with a median age of 62 (36--87) years, free blood glucose level of 9.61 ±1.02 mmol/l and disease duration of 9.28 ±4.56 years. The diabetic peripheral neuropathy group (DPN) was composed of 204 cases, of which 104 cases were male and 100 cases were female, with a median age of 59 (38--85) years, free blood glucose level of 9.22 ±3.56 mmol/l and diabetes duration of 9.98 ±4.34 years. Two hundred and forty healthy individuals (male 124, female 116), with a median age of 60 (41--78) years and free blood glucose level of 4.97 ±0.63 mmol/l were enrolled as the healthy control group (NC). They all underwent physical examination at the same hospital during the same period. All the 240 healthy individuals were assessed as normal in the oral 75 g glucose tolerance test (OGTT test). All of the subjects were Han people from Shandong Province, unrelated to one another. Subjects with nerve, retina, chronic cardiopulmonary diseases, liver and other organ diseases were excluded. The study was performed in accordance with the Declaration of Helsinki and was approved by the ethics committee of the hospital. Written informed consent was obtained from all subjects in advance.

Clinical and biochemical features {#S20004}
---------------------------------

The following clinical and biochemical data of each subject were collected. Body mass index (BMI = body weight (kg)/height (m)^2^) was measured. Fasting venous blood was taken, partly for the blood biochemistry analysis and VEGF detection, and partly for extraction of DNA. Fasting blood glucose (FBG) was measured by glucose oxidase. Blood lipids, liver function, renal function and electrolyte were analyzed by an automatic biochemical analyzer. The low pressure liquid chromatography column method was used to measure glycated hemoglobin (glycohemoglobin HbA~1c~).

ELISA {#S20005}
-----

The serum VEGF level was detected by a ELISA kit purchased from Wuhan Boster Biological Engineering Co., Ltd. In this study, the double antibody sandwich ELISA (DAS-ELISA) method was used. Experiments were performed strictly in accordance with the instructions. Briefly, 2 ml of fasting venous blood were taken. Sera were separated within 30 min by cryogenic centrifugation and stored at --70°C in a refrigerator. The anti-human VEGF monoclonal antibody was coated on the microtiter plate. Then standard samples and test samples with VEGF were added to bind the monoclonal antibody. After incubation, biotinylated anti-human VEGF was added and immune complexes were formed on the plate. Horseradish peroxidase-labeled streptavidin was added to bind the biotin on the antibody. After adding substrate and finally sulfuric acid to terminate the reaction, the OD value at 450 nm was measured. Vascular epidermal growth factor concentration is proportional to the OD 450 nm value. Vascular endothelial growth factor concentration in the samples was obtained by the standard curve.

EMG measurement {#S20006}
---------------

The diagnostic criteria \[[@CIT0009]\] for diabetic peripheral neuropathy included clinical symptoms, clinical signs, the electrophysiological diagnosis, quantified sensory evaluation and the evaluation of autonomic function. Diabetes patients with at least one aspect of abnormalities were diagnosed with diabetic peripheral neuropathy. The motor nerve conduction velocity (MCV) and the sensory nerve conduction velocity (SCV) of each patient were measured by Keypoint 11 surface electrode EMG (Denmark). To obtain the MCV value, stimuli were added at both the distal end and the proximal end. Signals were received at the corresponding distal end of the muscles. The MCV value was the quotient of the distance between the two stimulation points divided by the latency difference between the two points. The SCV value was obtained by the inverse method. Feeling waveform was made automatically by the average stacking technique of the machine. The SCV value was the quotient of the distance between the two stimulation points divided by the latency. The standard nerve conduction velocity was referred to Tang \[[@CIT0010]\].

Polymerase chain reaction-restriction fragment length polymorphism {#S20007}
------------------------------------------------------------------

Genomic DNA was extracted using a DNA extraction kit (TaKaRa). For polymerase chain reaction (PCR) amplification, peripheral blood leukocyte genomic DNA was used as a template. The primer sequences were designed according to the cDNA sequence of the VEGF206 isoform (GenBank accession numbers AF024710 and S85192) and Renner \[[@CIT0006]\] and synthesized by Songon Biotech (Shanghai) Co., Ltd. The sequences for the upstream and downstream primers were 5'-AAGGAAGAGGAGACTCTGCGCAGAGC-3', 5'-TAAATGTATGTATGTGGGTGGGTGTGTCTACAGG-3'. Restriction enzyme analysis: 10 µl of PCR products were digested with 5 U of restriction endonuclease *Nla* III (New England Biolabs). Digestion products and the reference marker were analyzed on 4% low-melting agarose gel. After electrophoresis, the gel was photographed and analyzed.

Statistical analysis {#S20008}
--------------------

All data were processed by SPSS 10.0 software. The Hardy-Weinberg equilibrium test was used for the examination of the gene frequencies of each group. Normally distributed data were expressed as mean ± standard deviation (*x* ± s). One-way analysis of variance (ANOVA) was used for the comparison between the clinical and biochemical data of each group. Distribution of genotypes and alleles was compared by χ^2^ test or R × C table column associated analysis. Logistic regression analysis was performed to analyze the related risk factors for type 2 diabetes neuropathy.

Results {#S0009}
=======

There are significant decreases in the frequency of 936T allele and VEGF 936 (CT+TT) genotype in patients with diabetic neuropathy {#S20010}
----------------------------------------------------------------------------------------------------------------------------------

Genotypes were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The sketch map for human 3\'UTR of VEGF is shown in [Figure 1A](#F0001){ref-type="fig"}: the location of the upstream primer is from number 148 to 173 and the downstream primer is from number 322 to 355. The 936C/T single-nucleotide polymorphisms in the VEGF gene lies in codon 232 (according to the nucleotide sequence from GenBank accession numbers AF024710). [Figure 1B](#F0001){ref-type="fig"} shows the representative results of PCR amplification. The length of the PCR products was 208 bp. Then the PCR products were digested with *Nla* III and the electrophoresis results are shown in [Figure 1C](#F0001){ref-type="fig"}. The digestion products were for CC genotype a 208 bp fragment, for TT genotype 122 bp and 86 bp fragments, and for CT genotype three fragments of 208 bp, 122 bp and 86 bp.

![SNP polymorphisms at C936T locus of the VEGF gene. **A** -- The C936T locus in the 3' UTR of the VEGF gene. **B** -- PCR products and 100 bp ladder marker. Lane 1: 100 bp ladder marker; lane 2-5: PCR products. **C** -- Genotype of VEGF gene C936T variant. lane 1: CT genotype; lane 2: TT genotype; lane 3: CC genotype; lane 4; 100 bp ladder marker](AMS-10-21906-g001){#F0001}

Polymerase chain reaction-restriction fragment length polymorphism test results showed that the 936 C/T polymorphism is prevalent in patients with type 2 diabetes and healthy control subjects ([Table I](#T0001){ref-type="table"}). As shown in [Table I](#T0001){ref-type="table"}, the genotype distribution in the NC group, DM group and DPN group did not show a significant deviation from the Hardy-Weinberg equilibrium (χ^2^ value of 0.620, 0.440 and 3.240, respectively, *p* = 0.733, *p* = 0.802, *p* = 0.198, respectively). Due to the extremely low frequency of TT genotype, carriers of the T allele were combined into CT+TT genotype before analysis according to the statistical method suggested by Krippl *et al*. \[[@CIT0007]\]. The T allele frequency and CT+TT genotype (carrying the T allele) frequency in the DPN group were significantly lower than those in the NC group (χ^2^ = 19.051 and 18.533, *p* \< 0.001 and *p* \< 0.001, respectively) and DM group (χ^2^ = 11.117 and 11.156, *p* = 0.001 and 0.001, respectively). However, there was no statistically significant difference (χ^2^ = 0.240 and 0.258, *p* = 0.624 and 0.611, respectively) in the three genotype (CC/CT+TT) frequencies and allele (C/T) frequencies between the DM group and the NC group.

###### 

Distribution of VEGF genotype and allele frequencies of the subjects in the NC, DM, and DPN group

  Group       Cases (*n*)   Genotype frequency, *n* (%)                                                        Allele frequency, *n* (%)                                                                                                                                            
  ----------- ------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------------
  NC group    240           141 (58.75)                                                                        99 (41.25)                                                                        365 (76.25)                                                                        115 (23.75)
  DM group    184           115 (62.50)                                                                        69 (37.50)                                                                        289 (78.53)                                                                        79 (21.47)
  DPN group   204           159 (77.94)^[a](#TF0001){ref-type="table-fn"},[b](#TF0002){ref-type="table-fn"}^   45 (22.06)^[a](#TF0001){ref-type="table-fn"},[b](#TF0002){ref-type="table-fn"}^   357 (87.50)^[a](#TF0001){ref-type="table-fn"},[b](#TF0002){ref-type="table-fn"}^   51 (12.50)^[a](#TF0001){ref-type="table-fn"},[b](#TF0002){ref-type="table-fn"}^

Compared with the NC group

p \< 0.05; compared with the DM group

p \< 0.05

The polymorphism 936C/T of VEGF is associated with the levels of plasma VEGF, HbA~1c~, blood glucose, blood lipids, and C-peptide {#S20011}
---------------------------------------------------------------------------------------------------------------------------------

As shown in [Table II](#T0002){ref-type="table"}, in all subjects, the clinical characteristics in different VEGF polymorphism genotypes such as sex ratio, age, duration of disease, blood pressure, BMI and high-density lipoprotein cholesterol (HDL-C) showed no significant difference (*p* \> 0.05) among the three different genotypes CC, CT and TT. Compared with CT+TT genotype (carrying the T allele), the blood glucose, blood lipids, HbA~1c~ and VEGF expression levels of the CC genotype were higher, while the C-peptide levels of the CC genotype were significantly lower (*p* \< 0.01, *p* \< 0.05). There were no significant differences in sex ratio, age, blood pressure and BMI among the NC group, DM group and DPN group (*p* \> 0.05). Also there were no significant differences in HbA~1c~, blood glucose and blood lipid levels between the DM group and DPN group (*p* \> 0.05). However, the HbA~1c~, blood glucose and blood lipid levels in the DM group and DPN group were higher than those in the NC group (*p* \< 0.05).

###### 

Comparison of clinical characteristics among subjects in different VEGF polymorphism genotypes (*x* ± s)

  Parameter            TT               CT                                                  CC
  -------------------- ---------------- --------------------------------------------------- -------------------------------------------------------------------------------------
  *N* (M/F)            32 (18/14)       181 (90/91)                                         415 (210/205)
  Age \[years\]        59 (36--83)      58 (39--83)                                         60 (41--87)
  Duration \[years\]   9.04 ±3.62       9.06 ±3.61                                          9.04 ±3.85
  FBG \[mmol/l\]       7.38 ±1.73       9.06 ±2.61^[a](#TF0003){ref-type="table-fn"}^       9.32 ±1.86^[b](#TF0004){ref-type="table-fn"},[c](#TF0005){ref-type="table-fn"}^
  PBG \[mmol/l\]       12.26 ±2.65      13.06 ±3.17^[a](#TF0003){ref-type="table-fn"}^      13.21 ±4.08^[b](#TF0004){ref-type="table-fn"},[d](#TF0006){ref-type="table-fn"}^
  HbA~1c~ \[%\]        6.98 ±1.78       7.99 ±1.32^[a](#TF0003){ref-type="table-fn"}^       7.96 ±2.1^[a](#TF0003){ref-type="table-fn"}^
  BMI \[kg/m^2^\]      22.16 ±2.54      22.85 ±2.43                                         22.79 ±2.56
  TC \[mmol/l\]        5.42 ±1.34       5.56 ±1.54^[a](#TF0003){ref-type="table-fn"}^       5.87 ±1.46^[b](#TF0004){ref-type="table-fn"},[c](#TF0005){ref-type="table-fn"}^
  TG \[mmol/l\]        1.51 ±0.65       1.65 ±0.59^[a](#TF0003){ref-type="table-fn"}^       1.75 ±0.87^[a](#TF0003){ref-type="table-fn"},[b](#TF0003){ref-type="table-fn"}^
  HDL-C \[mmol/l\]     1.68 ±0.31       1.71 ±0.25                                          1.73 ±0.43
  LDL-C \[mmol/l\]     2.71 ±0.46       2.81 ±0.36^[a](#TF0003){ref-type="table-fn"}^       2.84 ±0.39^[b](#TF0004){ref-type="table-fn"},[d](#TF0006){ref-type="table-fn"}^
  SBP \[mm Hg\]        132.43 ±12.34    126.65 ±11.34                                       126.65 ±11.87
  DBP \[mm Hg\]        81.65 ±8.34      79.65 ±8.51                                         81.45 ±7.99
  VEGF \[ng/l\]        445.32 ±119.76   598.38 ±122.44^[a](#TF0003){ref-type="table-fn"}^   621.33 ±110.23^[b](#TF0004){ref-type="table-fn"},[c](#TF0005){ref-type="table-fn"}^

Compared to TT genotype

p \< 0.05

p \< 0.01

compared to CT genotype

p \< 0.05

p \< 0.01

The incidence of diabetic peripheral neuropathy is significantly lower in the VEGF 936 (CT+TT) genotype (carrying the T allele) group {#S20012}
-------------------------------------------------------------------------------------------------------------------------------------

As shown in [Table III](#T0003){ref-type="table"}, in diabetic patients, the incidence of diabetic peripheral neuropathy in the CC genotype group was 57.97%, higher than the CT+TT genotype group (39.29%, χ^2^ = 5.578, *p* = 0.001) and CT genotype group (39.58%, χ^2^ = 4.837, *p* = 0.002). Compared with carriers of CT+TT genotypes and CT genotypes, the relative neuropathy occurrence risk (OR) for carriers of the CC genotype was 2.132 and 2.105, respectively, while the incidence of diabetic peripheral neuropathy was not significantly different between the CT genotype group and the CT+TT genotype group (χ^2^ = 0.001, *p* = 0.962).

###### 

Distribution of different VEGF polymorphism genotypes in type 2 diabetes with or without DPN

              DPN, *n* (%)                                                                      DM, *n* (%)                                                                       Total
  ----------- --------------------------------------------------------------------------------- --------------------------------------------------------------------------------- -------
  **CC**      159 (57.97)                                                                       115 (42.02)                                                                       274
  **CT**      39 (39.58)^[a](#TF0007){ref-type="table-fn"}^                                     59 (60.42)^[a](#TF0007){ref-type="table-fn"}^                                     98
  **CT+TT**   45 (39.29)^[b](#TF0008){ref-type="table-fn"},[c](#TF0009){ref-type="table-fn"}^   69 (60.71)^[b](#TF0008){ref-type="table-fn"},[c](#TF0009){ref-type="table-fn"}^   114

Compared to CC genotype (χ^2^ = 4.837, OR = 2.105, p = 0.002)

Compared to CC genotype (χ^2^ = 5.578, OR = 2.132, p = 0.001)

Compared to CT genotype (χ^2^ = 0.001, OR = 1.014, p = 0.962)

The 936 C to T mutation in the 3'-untranslated region of VEGF may be a protective factor against DPN {#S20013}
----------------------------------------------------------------------------------------------------

Logistic regression analysis was performed to assess the independent role of the VEGF genotype and other variables (including HbA~1c~ level, TC level, LDL-C level, VEGF concentration and VEGF 936C→T) in the incidence of DPN. In this analysis, the presence or absence of DPN was used as the dependent variable. As shown in [Table IV](#T0004){ref-type="table"}, the 936C/T polymorphism in the 3'-UTR of the VEGF gene was negatively related to the occurrence of DPN (β = --1.132, OR = 0.461, *p* = 0.004, 95% CI: 0.187--0.741). The remaining factors (VEGF concentration, HbA~1c~ and LDL-C) entered the regression equation with an OR \> 1, indicating that they were potent risk factors for DPN.

###### 

Logistic analysis of multiple risk factors for the association with DPN in type 2 diabetes patients

  Variable             CI                                                    
  -------------------- --------- ------- -------- ---------- ------- ------- -------
  HbA~1c~              0.298     0.101   8.715    0.003      1.347   1.105   1.641
  TC                   0.382     0.147   6.745    0.009      1.465   1.098   1.955
  LDL-C                0.650     0.265   6.004    0.014      1.915   1.139   3.219
  VEGF concentration   0.574     0.148   15.130   \< 0.001   1.776   1.330   2.372
  VEGF936C→T           --1.132   0.421   6.389    0.004      0.461   0.187   0.741

Discussion {#S0014}
==========

Our study showed that the distribution of 936C/T polymorphism in VEGF 3'-UTR is prevalent in the population. There were three genotypes: CC, CT and TT. The genotype distribution in the NC group, DM group and DPN group was in accordance with the Hardy-Weinberg equilibrium. Plasma VEGF levels were decreased sequentially in 936CC, CT and TT genotypes. The differences among the 3 genotypes were significant. These data suggest that the 936 C/T gene polymorphism in the 3'-UTR of the VEGF gene may lead to reduced VEGF expression. These data are consistent with the results reported by Krippl *et al*. \[[@CIT0007]\], Han *et al*. \[[@CIT0011]\] and Morohashi *et al*. \[[@CIT0012]\]. However, these findings are inconsistent with the results reported by Awata \[[@CIT0013]\]. This inconsistency may be due to the different detection methods and the different sources of VEGF. Kripple \[[@CIT0007]\], Han \[[@CIT0011]\], Morohashi and our lab measured the level of VEGF in the plasma by the ELISA method. The ELISA kits we used could only specifically detect VEGF121 and VEGF165. In contrast, Awata measured the level of VEGF in the serum. During the activation of platelets, large amounts of VEGF were released, which made the serum levels of VEGF often several times higher than the plasma levels of VEGF \[[@CIT0013]\]. This may be an important cause of the inconsistency.

Another finding of this study was that the CC genotype frequency in the DPN group was higher than that in the NC group and DM group, while the frequency of the CT+TT genotype (carrying the T allele) in the DPN group was significantly lower than the DM group and NC group. However, there were no significant differences in the CC, CT and TT genotype distribution between the DM group and NC group. Further analysis found interesting results. Compared with the DM group and NC group, the C allele frequency in the DPN group was higher. The T allele frequency in the DPN group was significantly lower than that in the DM group and NC group, while between the DM group and NC group, there were no significant differences in the C allele frequency and T allele frequency. These data suggest that VEGF gene polymorphism may be associated with DPN pathogenesis but irrelevant for the incidence risk of type 2 diabetes. In diabetic patients, the incidence of DPN in patients with CC genotype was 57.97%, higher than in patients with the CT+TT genotype (carrying the T allele) (39.29%). The OR value was 2.132, indicating that compared with patients carrying the CT+TT genotype, the relative occurrence risk of DPN in patients carrying the CC genotype was 2.132 times. These findings suggest that the 936 C/T polymorphism in the 3'-UTR of the VEGF gene is closely related to the incidence of DPN. The C allele may be a genetic marker of DPN occurrence, while the T allele may be a protective genetic marker of DPN. These data are consistent with studies reported by Tavakkoly-Bazzaz \[[@CIT0014]\].

The clinical and biochemical features such as blood pressure and glycolipid metabolic disorder between the CC genotype group and the CT+TT genotype group showed no significant difference. However, the levels of blood glucose, blood lipid, HbA~1c~ and VEGF expression of the 936CC genotype group were higher than those of the CT and TT genotype group. Similarly, levels of these clinical and biochemical features in the CT genotype group were also higher than those of the TT genotype group. Another study reported by Chowdhury *et al*. \[[@CIT0015]\] found that DNA can become glycosylated under a high glucose environment, leading to increased frequency of gene mutations and abnormal gene expression. Therefore the following questions need further study. As we know, the metabolic disorders in genetically susceptible individuals are more difficult to control \[[@CIT0016]\]. It is still not known whether loss of control of metabolic disorder promotes the gene mutation causing the high incidence of DPN. It needs to be further studied in the future whether the abnormal gene expression promotes glucose and lipid metabolic disorders, resulting in high levels of VEGF and increased risk of occurrence of DPN.

The occurrence of DPN is the outcome of the interaction of genetic and environmental factors \[[@CIT0017]\]. To exclude the effect of the interaction and screen out the most meaningful indicators of DPN, we assessed the role of many independent variables such as age, BMI, blood pressure, glycated hemoglobin, plasma C-peptide levels, blood lipids and genotype in the occurrence of DPN by logistic regression analysis. Logistic regression analysis showed that VEGF gene polymorphism was negatively correlated with DPN and that VEGF gene polymorphism may reduce the incidence risk of DPN. The factors HbA~1c~, LDL-C and VEGF entered the regression equation with an OR \> 1. So we assumed that they were risk factors for DPN occurrence. These data suggest that glycolipid metabolic disorder plays an important role in the occurrence and development of DPN.

In conclusion, the present study provides an insight into the association of 936 C/T gene polymorphism in the 3'-UTR of the VEGF gene with DPN. We have shown that the 936 C to T mutation in the 3'-UTR of VEGF may be a protective factor against DPN and negatively correlated with the level of plasma VEGF and the incidence of diabetic peripheral neuropathy. The correlations between gene polymorphisms and glucose and lipid metabolic disorders indicate that the occurrence of DPN is related to the interaction of genetic and environmental factors. Thus the prompt improvement and treatment of high blood glucose, high blood lipid, hypoxia and anemia caused by DM may reduce the risk of occurrence of DPN.
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